Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients

Launched by TAIWAN BIO THERAPEUTICS INC. · Feb 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called OmniMSC-AMI, which involves using special cells from bone marrow to help patients who have had a heart attack known as ST-segment elevation myocardial infarction (STEMI). The researchers want to find out if giving these cells into the heart right after a procedure to open blocked arteries is safe and can help improve heart function in the months that follow. They are currently recruiting participants who are between 20 and 80 years old and have experienced a heart attack within the last 6 hours.

To be eligible for this study, patients need to be diagnosed with an anterior STEMI, meaning they have specific signs of a heart attack on their heart monitor and a certain level of a heart-related protein in their blood. Participants in the trial will receive the new treatment and will be monitored closely to see how it affects their heart's ability to pump blood effectively. It's important to note that individuals with certain medical conditions, those who have had multiple heart attacks, or anyone pregnant or breastfeeding cannot take part in the trial. If you or a loved one meet the criteria and are interested in learning more, this could be an opportunity to contribute to important heart health research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patents, with age ≤20 or ≤80 years old.
• * Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction):
• • 1. Chest pain onset.
• • 2. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.
• • 3. TnT-I elevation.
• • Into emergency ≤ 6h upon AMI presentation.
• • Patients are willing to receive the treatment and sign the informed consent.
• Exclusion Criteria:
• • Age \< 20 or \>80 years old.
• • History of
• • 1. Malignancy.
• • 2. Sepsis (abnormal WBC count elevation).
• • 3. Hematologic disorder.
• • 4. AIDS.
• • 5. Advanced liver cirrhosis.
• • 6. CKD stage 5 with Ccr \<15 ml/min.
• • AMI occurrence \> 6 hours
• • Non-first AMI.
• • Pregnancy or breastfeeding.
• • Prison.
• • Cancer treatment within 2 years.
• • Expected lifespan \< 6 months.
• • Non-suitable candidate evaluated by PI.
• • Participating in other clinical trials.